Skip to main content
Premium Trial:

Request an Annual Quote

University of Kentucky Research Foundation, Gamida Cell, and Axis-Shield

The University of Kentucky Research Foundation has been awarded US Patent 7,345,160, “Aequorin and obelin mutants with differing wavelengths and bioluminescence.”
The inventors listed on the patent include Sylvia Daunert, Sapna Kamlakar Deo, Emre Dikici, and Laura Rowe.
According to its abstract, the patent relates to aequorin and obelin mutants whose emission is shifted with respect to wild type. The shift in emission is accomplished using a combination of mutations of amino acids within aequorin or obelin that affect bioluminescence; use of different types of chromophores, such as coelenterazines with variable emission characteristics; and modifications of the photoprotein with fluorophores that will allow for emission of light at longer wavelengths as a result of energy transfer. The patent also describes an assay using aequorin mutants to test for HIV-1 protease inhibitors, its abstract said.

Gamida Cell has been awarded US Patent 7,344,881, “Methods of expanding stem and progenitor cells and expanded cell populations obtained thereby.”
The inventors listed on the patent are Tony Peled, Avi Treves, and Oren Rosen.
The patent describes ex vivo and in vivo methods of expanding a population of stem and/or progenitor cells, while simultaneously reversibly inhibiting differentiation of these cells by providing them with an effective amount of at least one copper chelate, its abstract said.

Axis-Shield has been awarded US Patent 7,344,849, “Assay.”
The inventors listed on the patent are Erling Sundrehagen and Lars Orning.

According to the abstract, the patent discusses assay methods for the determination of cobalamin or vitamin B12 in a body fluid. The patent particularly focuses on assay methods for the metabolically active pool of cobalamin. Such assays comprise contacting a cell-free sample of a body fluid with an immobilized or immobilizable specific binding ligand for TC II or holo TC II, separating a ligand-bound fraction from a non-ligand-bound fraction, and then measuring the holo-TC II or TC-II bound cobalamin content.

The Scan

For Better Odds

Bloomberg reports that a child has been born following polygenic risk score screening as an embryo.

Booster Decision Expected

The New York Times reports the US Food and Drug Administration is expected to authorize a booster dose of the Pfizer-BioNTech SARS-CoV-2 vaccine this week for individuals over 65 or at high risk.

Snipping HIV Out

The Philadelphia Inquirer reports Temple University researchers are to test a gene-editing approach for treating HIV.

PLOS Papers on Cancer Risk Scores, Typhoid Fever in Colombia, Streptococcus Protection

In PLOS this week: application of cancer polygenic risk scores across ancestries, genetic diversity of typhoid fever-causing Salmonella, and more.